Elad Sharon

Also affiliated with Hebrew University of Jerusalem, Dana-Farber Cancer Institute, National Cancer Institute, Dana-Farber/Harvard Cancer Center, National Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

3.3Author DataRank

Indexed papers

10in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 10 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Ocular adverse events in PD-1 and PD-L1 inhibitors

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-002119

Top 11%

1.9DataRank

Top 11%48 citations

Shanda Finnigan, Howard Streicher, Helen Chen, James Murray, H. Nida Sen +2 more

Papers

Driven by 108 papers — median percentile 15. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002990

N/A

4.8DataRank · unranked

160 citations

Megan Othus, Sandip Pravin Patel, Chris Ryan, Ashish Sangal, Benjamin Powers +15 more

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02498-y

N/A

4.8DataRank · unranked

171 citations

Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia +28 more

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00658-6

N/A

4.8DataRank · unranked

234 citations

Anita Giobbie‐Hurder, Srinika Ranasinghe, Katrina Kao, Ana Lako, Junko Tsuji +32 more

Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

New England Journal of Medicine(2024)10.1056/nejmoa2312948

N/A

4.4DataRank · unranked

227 citations

Zhuoxin Sun, Ryan J. Mattison, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang +37 more

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002478

N/A

4.0DataRank · unranked

140 citations

Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl +24 more

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine(2024)10.1056/nejmoa2401726

N/A

3.9DataRank · unranked

151 citations

Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh +35 more

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2182

N/A

3.8DataRank · unranked

125 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30221-0

N/A

3.3DataRank · unranked

142 citations

Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David +12 more

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

New England Journal of Medicine(2023)10.1056/nejmoa2303383

N/A

3.3DataRank · unranked

158 citations

Elad Sharon, Geraldine O’Sullivan Coyne, Nancy Moore, Jared C. Foster, James Hu +26 more

Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers

Journal of Clinical Investigation(2021)10.1172/jci152670

N/A

2.1DataRank · unranked

86 citations

Leslie Cope, Amanda N. Ruggieri, Robert A. Anders, Anne M. Noonan, Laura W. Goff +24 more

Ocular adverse events in PD-1 and PD-L1 inhibitors

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-002119

Top 11%

1.9DataRank

Top 11%48 citations

Shanda Finnigan, Howard Streicher, Helen Chen, James Murray, H. Nida Sen +2 more

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia

Blood Advances(2022)10.1182/bloodadvances.2022008216

N/A

1.8DataRank · unranked

72 citations

Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Jae H. Park, Matthew J. Wieduwilt +12 more

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3726

N/A

1.1DataRank · unranked

24 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal +30 more

Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

The Lancet Haematology(2023)10.1016/s2352-3026(23)00157-6

N/A

0.847DataRank · unranked

32 citations

Page C. Moore, Milan Bimali, Jeanette Y. Lee, Michelle A. Rudek, Amy Chadburn +22 more

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents

Annals of Hematology(2023)10.1007/s00277-023-05552-4

N/A

0.726DataRank · unranked

23 citations

Rory M. Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E. Roe +18 more

Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma

Journal of Clinical Oncology(2024)10.1200/jco.24.00640

N/A

0.592DataRank · unranked

22 citations

Ramya Ramaswami, Irene Ekwede, Vanessa Eulo, Gaurav Goyal, Manoj Menon +22 more

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009074

N/A

0.503DataRank · unranked

12 citations

Megan Othus, Young Kwang Chae, Tridu R. Huynh, Benjamin Tan, Timothy M. Kuzel +9 more

SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer

Cancer(2024)10.1002/cncr.35243

N/A

0.496DataRank · unranked

15 citations

Elizabeth Guadarrama, Young Kwang Chae, Michael J. Dennis, Benjamin Powers, Chih‐Yi Liao +9 more

Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008724

Top 44%

0.427DataRank

Top 44%8 citations

Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame +28 more

Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae009

Top 44%

0.418DataRank

Top 44%6 citations

Sandip Pravin Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon +2 more

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2 -Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0633

N/A

0.414DataRank · unranked

9 citations

Victoria Wang, Jaime B. Hyman, Petros Grivas, Edith P. Mitchell, John Wright +17 more

A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma

Neuro-Oncology(2025)10.1093/neuonc/noaf079

N/A

0.394DataRank · unranked

9 citations

Andrea G. Manzanera, Caroline Duault, Edgar Gonzalez‐Kozlova, Lenika Lopez, Stuart A. Grossman +50 more

First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae297

Top 47%

0.385DataRank

Top 47%8 citations

Sandip Pravin Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon +2 more

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009128

N/A

0.380DataRank · unranked

9 citations

Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan +11 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma

npj Precision Oncology(2025)10.1038/s41698-024-00798-1

N/A

0.303DataRank · unranked

5 citations

Eleanor Cano-Linson, Young Kwang Chae, Shiruyeh Schokrpur, Christopher D. Lao, Benjamin Powers +13 more

Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-011760

N/A

0.245DataRank · unranked

4 citations

Jillian Fisher, Young Kwang Chae, Luisa M. Solis Soto, Anup Kasi, Bhavana Konda +27 more

Demographic Trends in NCI-sponsored Early-phase Clinical Trials (2000–2023): A Cohort Study

Cancer Discovery(2025)10.1158/2159-8290.cd-25-0112

Top 70%

0.165DataRank

Top 70%2 citations

Elad Sharon, Naoko Takebe, Maria Farooq

Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)

Therapeutic Advances in Medical Oncology(2024)10.1177/17588359241293401

N/A

0.104DataRank · unranked

1 citations

Megan Othus, Sandip Pravin Patel, David E. Gerber, Tawee Tanvetyanon, Hye Sung Kim +10 more

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9502

N/A

0DataRank · unranked

21 citations

James Moon, Zeynep Eroglu, Siwen Hu‐Lieskovan, William E. Carson, David A. Wada +15 more

Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9507

N/A

0DataRank · unranked

17 citations

Julie E. Stein, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I. Khushalani +13 more

A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11528

N/A

0DataRank · unranked

3 citations

Anthony P. Conley, James Lin Chen, Elizabeth J. Davis, Melissa Burgess, Albiruni Ryan Abdul Razak +13 more

Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba7564

N/A

0DataRank · unranked

3 citations

Justin Kline, Aleksandr Lazaryan, Nancy L. Bartlett, Francisco J. Hernandez‐Ilizaliturri, Farrukh T. Awan +13 more

A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4604

N/A

0DataRank · unranked

2 citations

Elad Sharon, Cheryl Ann Pickett-Gies, Lisa Mac, Julia C. Friend, Erin B. Purcell +14 more

Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3026

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Sarah Miller +15 more

1417 Utilization of immune-based response criteria in NCI-CTEP sponsored immunotherapy clinical trials

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.1417

N/A

0DataRank · unranked

1 citations

Alice P. Chen, Martha Kruhm, DAVID S. LOOSE, O’Hara Geraldine, Naoko Takebe +2 more

Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2508

N/A

0DataRank · unranked

0 citations

Melissa Moey, Xiao-Wei Cherie Tan, Mehak M Laharwal, Vanessa Hill, Nagabhishek Moka +6 more

Reply to S. Rossi et al and P. Palassin et al

日本体育学会大会号(2022)10.1200/jco.22.01928

N/A

0DataRank · unranked

0 citations

Douglas B. Johnson, Javid J. Moslehi, Elad Sharon, Abdul Rafeh Naqash

1469 A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic disease

(2022)10.1136/jitc-2022-sitc2022.1469

N/A

0DataRank · unranked

0 citations

Megan Othus, Young Kwang Chae, Michael J. Dennis, Sarah Gordon, David G. Mutch +7 more

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2293

N/A

0DataRank · unranked

27 citations

Megan Othus, Young Kwang Chae, Michael J. Dennis, Sarah Gordon, David G. Mutch +9 more

Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

The Lancet Oncology(2023)10.1016/s1470-2045(22)00742-2

N/A

0DataRank · unranked

25 citations

Heiko Schöder, Elad Sharon, Jedd D. Wolchok, Michael V. Knopp, Richard L. Wahl +18 more

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

EClinicalMedicine(2023)10.1016/j.eclinm.2023.101983

N/A

0DataRank · unranked

25 citations

Michael J. Martens, Jo‐Anne H. Young, Kavita V. Bhavsar, Jianqun Kou, Min Chen +23 more

The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad151

N/A

0DataRank · unranked

6 citations

Andrew G. Sikora, Himangi Marathe, Song Liu, Michael Demetriou, Lawrence Fong +8 more

A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.506

N/A

0DataRank · unranked

7 citations

Masha Kocherginsky, Parminder Singh, Zin Myint, Di Jiang, Elizabeth Wulff‐Burchfield +5 more

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps9603

N/A

0DataRank · unranked

7 citations

James Moon, Yana G. Najjar, Rupesh Kotecha, Vadim Spektor, Michael C. Wu +6 more

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4198

N/A

0DataRank · unranked

6 citations

Katherine A. Guthrie, Michael J. Pishvaian, Kim Anna Reiss, Andrew M. Lowy, Davendra Sohal +7 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5517

N/A

0DataRank · unranked

4 citations

Megan Othus, Sandip Pravin Patel, Robert P. Edwards, Jennifer Scalici, Liam Il‐Young Chung +8 more

ETCTN 10476: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps639

N/A

0DataRank · unranked

3 citations

Mark Yarchoan, Judy Murray, Hao Wang, John Joseph Wright, Elad Sharon +3 more

Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3108

N/A

0DataRank · unranked

3 citations

Zihan Wei, David S. Hong, Edith P. Mitchell, James A. Zwiebel, Elad Sharon +15 more

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3022

N/A

0DataRank · unranked

2 citations

Alice P. Chen, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Naoko Takebe +15 more

Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2504

N/A

0DataRank · unranked

1 citations

Sandip Pravin Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon +2 more

Expanding eligibility criteria for renal and liver function in NCI-sponsored immunotherapy clinical trials.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e13610

N/A

0DataRank · unranked

1 citations

Alice P. Chen, Martha Kruhm, DAVID S. LOOSE, Geraldine O’Sullivan Coyne, Naoko Takebe +2 more

A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11533

N/A

0DataRank · unranked

1 citations

Brian Ko, Brian A. Van Tine, Anthony P. Conley, Elizabeth J. Davis, Melissa Burgess +12 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336

Top 100%

0DataRank

Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336.v1

Top 100%

0DataRank

Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

(2023)10.1158/1078-0432.c.6530837

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.c.6532346.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1

N/A

0DataRank · unranked

0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16330

N/A

0DataRank · unranked

0 citations

Elizabeth Guadarrama, Young Kwang Chae, Chih‐Yi Liao, Anup Kasi, Grace R. Tarabay +12 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11516

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan +10 more

Signal detection in real‐world data and confirmation in clinical trials: Diabetes as a case study for a conversation worth having

Cancer(2023)10.1002/cncr.34939

N/A

0DataRank · unranked

0 citations

Megan Othus, Zoe Quandt, Elad Sharon

SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study

Clinical Infectious Diseases(2024)10.1093/cid/ciae291

N/A

0DataRank · unranked

25 citations

Michael J. Martens, Jo‐Anne H. Young, Kavita V. Bhavsar, Jianqun Kou, Min Chen +25 more

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1728

N/A

0DataRank · unranked

7 citations

Gurkamal Chatta, Rohit K. Jain, Helen Moon, Scott E. Delacroix, Alana Fang +10 more

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

Lung Cancer(2024)10.1016/j.lungcan.2024.107928

N/A

0DataRank · unranked

16 citations

Jun Vivien Yin, Penelope A. Bradbury, David J. Kwiatkowski, Shiven B. Patel, Lyudmila Bazhenova +24 more

SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0606

N/A

0DataRank · unranked

11 citations

Megan Othus, Sandip Pravin Patel, Kelly J. Wilkinson, Emily M. Whitman-Purves, Jayanthi Lea +21 more

Using multi-scale genomics to associate poorly annotated genes with rare diseases

Genome Medicine(2024)10.1186/s13073-023-01276-2

N/A

0DataRank · unranked

7 citations

Dana Sherill-Rofe, Lara Kamal, Idit Bloch, Fouad Zahdeh, Elad Sharon +11 more

Navigating the Complexities of Artificial Intelligence–Enabled Real-World Data Collection for Oncology Pharmacovigilance

JCO Clinical Cancer Informatics(2024)10.1200/cci.24.00051

N/A

0DataRank · unranked

7 citations

Leo Anthony Celi, Elad Sharon, Danielle S. Bitterman, Jack Gallifant

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1957

N/A

0DataRank · unranked

6 citations

Lucy Corthell, Sandip Pravin Patel, Robert P. Edwards, Jennifer Scalici, Hye Sung Kim +10 more

Evolving patterns in systemic treatment utilization and survival among older patients with advanced cutaneous melanoma

Cancer Medicine(2024)10.1002/cam4.70131

N/A

0DataRank · unranked

4 citations

Lindsey Enewold, Elad Sharon, Jeremy L. Warner, Amy J. Davidoff, Chris Zeruto +2 more

SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101)

medRxiv(2024)10.1101/2024.01.24.24301058

N/A

0DataRank · unranked

2 citations

Michael J. Martens, Jo‐Anne H. Young, Kavita V. Bhavsar, Jianqun Kou, Min Chen +25 more

The use of large language models to enhance cancer clinical trial educational materials

arXiv (Cornell University)(2024)10.48550/arxiv.2412.01955

N/A

0DataRank · unranked

1 citations

Varshney, Aman, Shan Chen, Vikram Goddla, Jack Gallifant, Patrick Doyle +13 more

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial

Nature Communications(2025)10.1038/s41467-024-55200-2

N/A

0DataRank · unranked

18 citations

Dmitriy Zamarin, Wei Deng, Heather A. Lankes, Giulio Pesci, Hayeon Kim +19 more

Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.13727

N/A

0DataRank · unranked

14 citations

Marc Machaalani, Razane El Hajj Chehade, Amin H. Nassar, Rashad Nawfal, Michael P. Manos +20 more

The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup

Nature Reviews Nephrology(2025)10.1038/s41581-025-01031-3

N/A

0DataRank · unranked

7 citations

Marlies Ostermann, Claudio Ronco, Karen K. Ballen, Laura Cosmai, Roberta Fenoglio +32 more

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-011865

N/A

0DataRank · unranked

5 citations

Yee-Ming Melody Cheung, Cherie Chiang, Emily J. Gallagher, Ole‐Petter R. Hamnvik, Jennifer S. Mammen +32 more

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications(2025)10.1002/cac2.70020

N/A

0DataRank · unranked

3 citations

Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic +12 more

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis

Blood Advances(2025)10.1182/bloodadvances.2025016845

N/A

0DataRank · unranked

2 citations

Tamer Othman, Paul Frankel, Christopher Ruel, Christina Poh, Samantha Herbert +20 more

Incidence and survival of rare cancers in the US and Europe

Cancer Medicine(2020)10.1002/cam4.3137

N/A

0DataRank · unranked

48 citations

Gemma Gatta, Annalisa Trama, Alice Bernasconi, Elad Sharon, Riccardo Capocaccia +3 more

Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?

Radiation Research(2020)10.1667/rade-20-00211.1

N/A

0DataRank · unranked

46 citations

Gayle E. Woloschak, Andrea L. DiCarlo, Jeffrey C. Buchsbaum, Dörthe Schaue, Arnab Chakravarti +20 more

Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis

JAMA Network Open(2020)10.1001/jamanetworkopen.2020.0032

N/A

0DataRank · unranked

25 citations

Sandra G. Williams, Lawrence Yao, Suresh Maharjan, Julius Strauss, Elad Sharon +9 more

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Oncotarget(2020)10.18632/oncotarget.27784

N/A

0DataRank · unranked

20 citations

Shivaani Kummar, Robert Meehan, T. Khanh, Jerry M. Collins, Larry Anderson +20 more

Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers

CHEST Journal(2020)10.1016/j.chest.2020.04.068

N/A

0DataRank · unranked

35 citations

Idrees Mian, Camille Tlemsani, Lőrinc Sándor Pongor, Nobuyuki Takahashi, Kathleen Maignan +18 more

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5022

N/A

0DataRank · unranked

55 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, Scott Lucia, William T. Lowrance +11 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1073

N/A

0DataRank · unranked

32 citations

Megan Othus, Sandip Pravin Patel, Young Kwang Chae, Kathy D. Miller, Rashmi Chugh +8 more

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps1102

N/A

0DataRank · unranked

10 citations

Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisín M. Connolly, Erin Roesch, Anosheh Afghahi +15 more

A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3158

N/A

0DataRank · unranked

6 citations

María E. Suarez‐Almazor, Jeane Painter, Tanner M. Johanns, Michael Dougan, Laura C. Cappelli +15 more

A phase I and randomized phase II etctn study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in relapsed and refractory diffuse large B-cell lymphoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps8072

N/A

0DataRank · unranked

5 citations

Santosha A. Vardhana, Anita Kumar, Mehrdad Abedi, Rasmus T. Hoeg, Elad Sharon +2 more

Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3154

N/A

0DataRank · unranked

5 citations

Elad Sharon, Jennifer Le‐Rademacher, Erin Twohy, Tyler Zemla, Yujia Wen +8 more

S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps10090

N/A

0DataRank · unranked

1 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +8 more

A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps9638

N/A

0DataRank · unranked

1 citations

Richard D. Hall, Andreas Saltos, Gregory A. Otterson, Ming Tan, Sacha Gnjatic +5 more

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-003277

N/A

0DataRank · unranked

118 citations

David M. Faleck, Anusha Shirwaikar Thomas, Jessica Harris, Deepika Satish, Xuemei Wang +13 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0329

N/A

0DataRank · unranked

71 citations

Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, Shivaani Kummar, T. Khanh, Ashley Bruns +19 more

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2480

N/A

0DataRank · unranked

27 citations

Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do +17 more

Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa

Aids Reviews(2021)10.24875/aidsrev.20000005

N/A

0DataRank · unranked

9 citations

Elad Sharon, Jonathan D. Strope, Prabha Chandrasekaran, Ravie Kem, Robert Yarchoan +5 more

A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps2676

N/A

0DataRank · unranked

29 citations

Michael Dougan, Sarthak Gupta, Laura C. Cappelli, Tamiko R. Katsumoto, Osama E. Rahma +15 more

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11519

N/A

0DataRank · unranked

50 citations

Geraldine O’Sullivan Coyne, Nancy Moore, Elad Sharon, Naoko Takebe, Kristin Fino +15 more

Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3088

N/A

0DataRank · unranked

5 citations

Geraldine O’Sullivan Coyne, Naoko Takebe, Abdul Rafeh Naqash, Jessica Mukherjee, Ashley Bruns +12 more

S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps9585

N/A

0DataRank · unranked

3 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +9 more

Cross-species identification of cancer-resistance associated genes uncovers their relevance to human cancer risk

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.05.19.444895

N/A

0DataRank · unranked

1 citations

Kuoyuan Cheng, Lamis Naddaf, Elad Sharon, Lipika R. Pal, Padma Sheila Rajagopal +7 more

1073P Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1458

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Megan Othus, Amy K. Darke, Ahmad A. Tarhini, John M. Kirkwood +5 more

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

npj Breast Cancer(2022)10.1038/s41523-022-00500-3

N/A

0DataRank · unranked

54 citations

Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski +21 more

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

npj Precision Oncology(2022)10.1038/s41698-022-00256-w

N/A

0DataRank · unranked

43 citations

Zihan Wei, Ranee Mehra, Alice T. Shaw, Christopher H. Lieu, Patrick M. Forde +24 more

Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1123

N/A

0DataRank · unranked

13 citations

Mark Yarchoan, Subir Goyal, Yuan Liu, Elad Sharon, Helen X. Chen +7 more

Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005128

N/A

0DataRank · unranked

13 citations

Kathryn Lurain, Julius Strauss, Steven P. Fling, Elad Sharon, Anna K. Wright +8 more

Elad Sharon

Indexed papers

Top data-sharing exemplar

Papers